Glucagon Market
Glucagon Market Size, Share & Trends Analysis Report by Product Type (Injectable and Nasal), by Application (Emergency Kits, General Use, Diagnostics & Motility, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period, (2026-2035)
Industry Overview
Glucagon market was valued at $350.8 million in 2025 and is projected to reach $616.4 million by 2035, growing at a CAGR of 5.9% during the forecast period (2026-2035). Rising awareness regarding the management of severe hypoglycemia is supporting steady demand for glucagon products across clinical and home care settings. The introduction of user-friendly delivery formats, including nasal and ready-to-use injectable options, is improving treatment accessibility and adherence. Increasing diagnosis rates of diabetes and expanded patient education initiatives are contributing to higher prescription volumes. Healthcare providers are prioritizing rapid emergency response solutions, which is reinforcing product adoption in both hospital and outpatient environments. Continued product innovation and broader pharmacy availability are expected to sustain market expansion over the forecast period.
Market Dynamics
Rising Demand for Rapid-Acting Hypoglycemia Rescue Solutions
The increasing prevalence of diabetes requiring intensive glucose management is a major factor supporting demand for glucagon products. Healthcare providers are emphasizing rapid treatment options for severe hypoglycemia, which is encouraging higher prescription rates of ready-to-use formulations. The introduction of nasal delivery and prefilled injectables is improving ease of administration for caregivers and non-clinical users, supporting adoption in home settings. Clinical guidelines recommending accessible rescue therapies are influencing procurement decisions across hospitals and pharmacies. Expansion of patient education programs focused on emergency preparedness is also contributing to consistent product utilization. Pharmaceutical manufacturers are investing in stability improvements and simplified dosing, which enhances usability across diverse patient groups. Growing availability across retail and online pharmacy channels is further strengthening market penetration.
Regulatory Support and Formulation Advancements Driving Product Adoption
Regulatory support for safer emergency treatment solutions is encouraging innovation across injectable and nasal glucagon formats. Healthcare systems are prioritizing therapies that reduce treatment delays during hypoglycemic events, leading to wider integration of user-friendly rescue products. Reimbursement coverage across several regions is improving patient access and supporting recurring product demand. Advancements in formulation technology are extending shelf life and reducing preparation steps, which increases acceptance among clinicians and caregivers. Expansion of outpatient diabetes management programs is reinforcing the need for portable emergency solutions. Pharmaceutical companies are also strengthening distribution strategies through retail and hospital pharmacy networks, improving product availability at the point of care. Continuous focus on treatment adherence and rapid response protocols is expected to sustain growth across the forecast period.
Market Segmentation
- Based on the product type, the market is segmented into injectable and nasal.
- Based on the application, the market is segmented into emergency kits, general use, diagnostics & motility, and others.
- Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Injectable Glucagon Maintaining Strong Revenue Share
Injectable glucagon remains a leading sub-segment due to established clinical use and strong physician familiarity in emergency hypoglycemia management. Hospitals and outpatient care providers continue to rely on injectable formats where rapid administration protocols are already standardized. Companies such as Eli Lilly and Xeris Biopharma maintain a significant presence through ready-to-use formulations that reduce preparation time. Recent product development has focused on improving formulation stability and extending shelf life to support inventory efficiency across pharmacies. Procurement patterns indicate consistent demand driven by institutional purchasing contracts and long-standing treatment guidelines. Ongoing refinements in delivery devices are strengthening adoption across both professional and caregiver settings.
Online Pharmacies Emerging as a High-Growth Distribution Channel
Online pharmacy platforms are recording accelerated expansion as patients and caregivers increasingly prefer direct access to emergency medications through digital prescription services. Growth is supported by improved reimbursement processing, expanded e-commerce healthcare infrastructure, and broader availability of nasal and ready-to-use injectable products. Major pharmaceutical manufacturers are strengthening digital distribution partnerships to enhance supply chain reach and refill management. Subscription-based refill models and home delivery services are encouraging recurring purchases, particularly among patients managing chronic diabetes. Regulatory acceptance of telehealth consultations is also contributing to prescription fulfillment through online channels. Increased emphasis on convenience and rapid delivery timelines continues to drive this segment’s momentum within the distribution landscape.
Regional Outlook
The global Glucagon market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Demonstrating Steady Product Adoption and Innovation Focus
The market in North America continues to expand due to established diabetes management frameworks and strong access to emergency care therapies. Pharmaceutical companies such as Eli Lilly and Xeris Biopharma maintain a visible presence through nasal and ready-to-use injectable formulations. Demand is supported by structured reimbursement systems and consistent prescribing practices across hospitals and retail pharmacies. Recent trends indicate a gradual shift toward simplified delivery formats that reduce preparation time during hypoglycemic events. Distribution partnerships with pharmacy chains are strengthening product availability in outpatient settings. Ongoing investment in formulation improvements is reinforcing long-term market stability across the region.
Europe Advancing Through Regulatory Alignment and Pharmacy Accessibility
European markets are witnessing gradual growth supported by standardized clinical guidance and increasing awareness of severe hypoglycemia management. Manufacturers, including Novo Nordisk and regional generic suppliers, are expanding access through hospital and community pharmacy networks. Healthcare systems are prioritizing therapies that support patient self-administration, encouraging uptake of nasal delivery options. Recent developments highlight broader reimbursement coverage and inclusion of emergency rescue treatments within national treatment pathways. Emphasis on cost-effective procurement is shaping competitive positioning among branded and generic products. Continued focus on patient safety and streamlined prescribing processes is contributing to steady regional demand.
Market Players Outlook
The major companies operating in the global glucagon market include Eli Lilly and Company, Amphastar Pharmaceuticals, Inc., Novo Nordisk A/S, Xeris Biopharma Holdings, Inc., Fresenius SE & Co. KGaA (Fresenius Kabi), among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In August 2025, Lupin introduced a 1 mg/vial glucagon emergency kit in the US, expanding competition within injectable rescue therapies.
- In March 2025, Xeris received approval for a supplemental application allowing Gvoke VialDx (glucagon) to be used as a diagnostic aid, expanding beyond emergency hypoglycemia treatment.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global glucagon market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Glucagon Market Sales Analysis – Product Type | Application | Distribution Channel ($ Million)
- Glucagon Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Glucagon Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Glucagon Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Glucagon Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Glucagon Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Glucagon Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Glucagon Market Revenue and Share by Manufacturers
- Glucagon Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Eli Lilly and Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Amphastar Pharmaceuticals, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novo Nordisk A/S,
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Xeris Biopharma Holdings, Inc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Fresenius SE & Co. KGaA (Fresenius Kabi)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Eli Lilly and Company
- Key Company Analysis
- Global Glucagon Market Sales Analysis by Product Type ($ Million)
- Injectable
- Nasal
- Global Glucagon Market Sales Analysis by Application ($ Million)
- Emergency Kits
- General Use
- Diagnostics & Motility
- Others
- Global Glucagon Market Sales Analysis by Distribution Channel ($ Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Analysis
- North American Glucagon Market Sales Analysis – Product Type | Application | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Glucagon Market Sales Analysis – Product Type | Application | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Glucagon Market Sales Analysis – Product Type | Application | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Glucagon Market Sales Analysis – Product Type | Application | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AptarGroup, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aurobindo Pharma Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biocon Biologics Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CSPC Pharmaceutical Group
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hikma Pharmaceuticals PLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jiangsu Hengrui Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck KGaA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shanghai Fosun Pharmaceutical
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Tonghua Dongbao Pharmaceutical
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viatris Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Wockhardt Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ypsomed AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zealand Pharma A/S
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Lifesciences Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AptarGroup, Inc.
1. Global Glucagon Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. Global Injectable Glucagon Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Nasal Glucagon Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Glucagon Market Research and Analysis by Application, 2025–2035 ($ Million)
5. Global Glucagon in Emergency Kit Use Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Glucagon in General Use Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Glucagon in Diagnostics & Motility Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Glucagon in Other Applications Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Glucagon Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
10. Global Glucagon in Hospital Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Glucagon in Retail Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Glucagon in Online Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Glucagon Market Research and Analysis by Region, 2025–2035 ($ Million)
14. North American Glucagon Market Research and Analysis by Country, 2025–2035 ($ Million)
15. North American Glucagon Market Research and Analysis by Product Type, 2025–2035 ($ Million)
16. North American Glucagon Market Research and Analysis by Application, 2025–2035 ($ Million)
17. North American Glucagon Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
18. European Glucagon Market Research and Analysis by Country, 2025–2035 ($ Million)
19. European Glucagon Market Research and Analysis by Product Type, 2025–2035 ($ Million)
20. European Glucagon Market Research and Analysis by Application, 2025–2035 ($ Million)
21. European Glucagon Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
22. Asia-Pacific Glucagon Market Research and Analysis by Country, 2025–2035 ($ Million)
23. Asia-Pacific Glucagon Market Research and Analysis by Product Type, 2025–2035 ($ Million)
24. Asia-Pacific Glucagon Market Research and Analysis by Application, 2025–2035 ($ Million)
25. Asia-Pacific Glucagon Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
26. Rest of the World Glucagon Market Research and Analysis by Region, 2025–2035 ($ Million)
27. Rest of the World Glucagon Market Research and Analysis by Product Type, 2025–2035 ($ Million)
28. Rest of the World Glucagon Market Research and Analysis by Application, 2025–2035 ($ Million)
29. Rest of the World Glucagon Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
1. Global Glucagon Market Share by Product Type, 2025 vs 2035 (%)
2. Global Injectable Glucagon Market Share by Region, 2025 vs 2035 (%)
3. Global Nasal Glucagon Market Share by Region, 2025 vs 2035 (%)
4. Global Glucagon Market Share by Application, 2025 vs 2035 (%)
5. Global Glucagon in Emergency Kit Use Market Share by Region, 2025 vs 2035 (%)
6. Global Glucagon in General Use Market Share by Region, 2025 vs 2035 (%)
7. Global Glucagon in Diagnostics & Motility Market Share by Region, 2025 vs 2035 (%)
8. Global Glucagon in Other Applications Market Share by Region, 2025 vs 2035 (%)
9. Global Glucagon Market Share by Distribution Channel, 2025 vs 2035 (%)
10. Global Glucagon in Hospital Pharmacies Market Share by Region, 2025 vs 2035 (%)
11. Global Glucagon in Retail Pharmacies Market Share by Region, 2025 vs 2035 (%)
12. Global Glucagon in Online Pharmacies Market Share by Region, 2025 vs 2035 (%)
13. Global Glucagon Market Share by Region, 2025 vs 2035 (%)
14. US Glucagon Market Size, 2025–2035 ($ Million)
15. Canada Glucagon Market Size, 2025–2035 ($ Million)
16. UK Glucagon Market Size, 2025–2035 ($ Million)
17. France Glucagon Market Size, 2025–2035 ($ Million)
18. Germany Glucagon Market Size, 2025–2035 ($ Million)
19. Italy Glucagon Market Size, 2025–2035 ($ Million)
20. Spain Glucagon Market Size, 2025–2035 ($ Million)
21. Russia Glucagon Market Size, 2025–2035 ($ Million)
22. Rest of Europe Glucagon Market Size, 2025–2035 ($ Million)
23. India Glucagon Market Size, 2025–2035 ($ Million)
24. China Glucagon Market Size, 2025–2035 ($ Million)
25. Japan Glucagon Market Size, 2025–2035 ($ Million)
26. South Korea Glucagon Market Size, 2025–2035 ($ Million)
27. Australia and New Zealand Glucagon Market Size, 2025–2035 ($ Million)
28. ASEAN Economies Glucagon Market Size, 2025–2035 ($ Million)
29. Rest of Asia-Pacific Glucagon Market Size, 2025–2035 ($ Million)
30. Latin America Glucagon Market Size, 2025–2035 ($ Million)
31. Middle East and Africa Glucagon Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
